Respiratory Syncytial Virus: Epidemiology, Burden of Disease, and Clinical Update
- PMID: 38944477
- DOI: 10.1016/j.yapd.2024.02.003
Respiratory Syncytial Virus: Epidemiology, Burden of Disease, and Clinical Update
Abstract
Respiratory syncytial virus (RSV) is a common viral pathogen that accounts about 33 million cases of acute lower respiratory tract infection (LRTI) worldwide in children under the age of 5 years each year. High-risk populations, particularly preterm infants, those with underlying chronic lung disease, congenital heart disease, or compromised immune systems, are afflicted most significantly. RSV infection is characterized by significant amount of mucus and submucosal edema in the respiratory tract, leading to congestion and, oftentimes, significant respiratory distress. Antigen- and PCR-based testing are used to diagnose RSV infection.
Keywords: Immunoprophylaxis; RSV; Respiratory syncytial virus; Seasonality; Surveillance.
Copyright © 2024 Elsevier Inc. All rights reserved.
Conflict of interest statement
Disclosure The following disclosures in relation to Dr C.M. Espinosa: Advisory board for Sanofi, Advisory board for Gilead, principal investigator for sponsored research by AstraZeneca, Merck and Enanta, principal investigator Clinetics, and past speaker bureau for AstraZeneca.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
